Oncopeptides
Develops targeted therapies for hematological cancers using peptide-drug conjugate technology.
ONCO | ST
Overview
Corporate Details
- ISIN(s):
- SE0009414576 (+4 more)
- LEI:
- 549300J9WWQ5CBYQ1M77
- Country:
- Sweden
- Address:
- Luntmakargatan 46, 111 37 Stockholm
- Website:
- https://www.oncopeptides.com/en
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Oncopeptides AB is a biotechnology company focused on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers, particularly hematological diseases. Founded in 2000, the company leverages its proprietary Peptide Drug Conjugate technology platforms to develop innovative treatments. Its lead product, Pepaxti® (melflufen), is a treatment for adult patients with relapsed refractory multiple myeloma (RRMM). Oncopeptides is actively commercializing Pepaxti in Europe and conducts real-world evidence studies to support the drug's effectiveness and tolerability in clinical practice. The company's mission is to address significant unmet medical needs and provide hope to cancer patients through scientific innovation.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-10-08 09:50 |
ISS
|
English | 10.5 KB | ||
| 2025-09-30 10:00 |
Declaration of Voting Results & Voting Rights Announcements
Antal aktier och röster i Oncopeptides
|
Swedish | 68.1 KB | ||
| 2025-09-30 10:00 |
Declaration of Voting Results & Voting Rights Announcements
Number of shares and votes in Oncopeptides
|
English | 67.7 KB | ||
| 2025-09-17 08:30 |
Share Issue/Capital Change
Oncopeptides’ rights issue oversubscribed to approximately 157 percent
|
English | 86.0 KB | ||
| 2025-09-17 08:30 |
Share Issue/Capital Change
Oncopeptides företrädesemission övertecknad till cirka 157 procent
|
Swedish | 86.2 KB | ||
| 2025-08-29 09:45 |
Major Shareholding Notification
|
Swedish | 10.5 KB | ||
| 2025-08-28 10:41 |
Major Shareholding Notification
|
Swedish | 10.5 KB | ||
| 2025-08-28 08:15 |
Share Issue/Capital Change
Oncopeptides publishes disclosure document regarding rights issue
|
English | 91.2 KB | ||
| 2025-08-28 08:15 |
Share Issue/Capital Change
Oncopeptides offentliggör informationsdokument avseende företrädesemission
|
Swedish | 92.7 KB | ||
| 2025-08-25 20:40 |
Share Issue/Capital Change
Oncopeptides enters into additional guarantee commitments, rights issue fully g…
|
English | 83.4 KB | ||
| 2025-08-25 20:40 |
Share Issue/Capital Change
Oncopeptides ingår ytterligare garantiåtaganden, företrädesemissionen fullt gar…
|
Swedish | 85.1 KB | ||
| 2025-08-25 10:10 |
Major Shareholding Notification
|
Swedish | 10.6 KB | ||
| 2025-08-21 08:00 |
Interim Report
|
Swedish | 580.9 KB | ||
| 2025-08-21 08:00 |
Interim Report
|
English | 597.7 KB | ||
| 2025-08-21 07:59 |
Share Issue/Capital Change
Oncopeptides carries out rights issue of approximately SEK 150 million and prov…
|
English | 110.4 KB |
Automate Your Workflow. Get a real-time feed of all Oncopeptides filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Oncopeptides via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-04-15 | David Augustsson | Other | Buy | 1,250 | 6,350.00 SEK |
| 2024-04-15 | David Augustsson | Other | Buy | 1,250 | 6,312.50 SEK |
| 2024-04-15 | David Augustsson | Other | Buy | 438 | 2,225.04 SEK |
| 2024-04-15 | David Augustsson | Other | Buy | 60 | 303.60 SEK |
| 2024-04-15 | David Augustsson | Other | Buy | 2 | 10.02 SEK |
| 2023-09-08 | David Augustsson | Other | Buy | 2,296 | 17,706.75 SEK |
| 2023-08-10 | David Augustsson | Other | Buy | 1,704 | 14,995.20 SEK |
| 2023-05-04 | Nicolaas Bakker | Other | Buy | 5,000 | 42,380.00 SEK |
| 2022-10-10 | Nicolaas Bakker | Other | Buy | 15,000 | 164,400.00 SEK |
| 2022-08-30 | Per Wold-Olsen | Other | Buy | 2,050 | 55,350.00 SEK |
/other/Diamyd_Medical_AB_publ-logo.png){kind=logo}
